This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

On behalf of the American Society for Reproductive Medicine, Birmingham, Ala, the Menopause Special Interest Group, Birmingham, would like to comment on the recent review article by John A. Blakely,¹ who reassessed the findings of the Heart and Estrogen/Progestin Replacement Study (HERS).² The HERS study was conducted to determine if hormone replacement therapy (HRT) reduces the number of coronary events in women who already have coronary artery disease (ie, a secondary prevention trial). The results included the unexpected finding that an early increase in coronary events is associated with daily treatment with both 0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate at the same time in women with established coronary disease. Over the 4-year period of observation, however, there was no statistical difference between the women receiving estrogen-progestin and those receiving placebo. Dr Blakely suggests that the HRT precipitated this increase in early cardiovascular events. He . . . [Full Text of this Article]

RELATED ARTICLE

The Heart and Estrogen/Progestin Replacement Study Revisited: Hormone Replacement Therapy Produced Net Harm, Consistent With the Observational Data
John A. Blakely
Arch Intern Med. 2000;160(19):2897-2900.
ABSTRACT | FULL TEXT